中医药联合EGFR-TKI类药物治疗晚期非小细胞肺癌研究进展
Research Progress of TCMCombined with EGFR-TKI Drugs in the Treatment of Advanced Non-Small Cell Lung Cancer
摘要: 近年来，肺癌发病率及死亡率高居癌症首位，但绝大多数患者在首诊时已经是晚期，失去手术根治治疗的机会，辅助放化疗作为一线推荐，其疗效虽然客观，但现已进入平台期，靶向治疗日益成为首选治疗手段，但仍然存在一定毒副作用及耐药性，而中医学因其特有的辨证论治体系以及增效减毒的特点，可以缓解相应副作用，故联合治疗将取得更好的疗效。本文将对皮细胞生长因子受体(epidermal growth factor receptor, EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)类药物的研究进展，中医药联合靶向治疗的临床研究进行综合阐述，为中西医结合治疗提供一定理论依据。
Abstract: In recent years, lung cancer incidence and mortality of cancer at first, but the vast majority of pa-tients in the first option is already late, loses the chance of radical surgery treatment, fractionation is recommended as a line, although their effectiveness is objective, has now entered the platform period, targeted therapy has become a preferred treatment, there is still a certain side effect and drug resistance, and traditional Chinese medicine because of its unique system of syndrome dif-ferentiation and the characteristic of the attenuated synergies, can alleviate the corresponding side effects, so the curative effect of combination therapy will be better. In this paper, the research progress of egfr-tki drugs and the clinical research of traditional Chinese medicine combined with targeted therapy will be comprehensively described, providing a theoretical basis for the inte-grated treatment of traditional Chinese and western medicine.
文章引用：郭文韬, 寿伟臻. 中医药联合EGFR-TKI类药物治疗晚期非小细胞肺癌研究进展[J]. 临床医学进展, 2020, 10(4): 664-669. https://doi.org/10.12677/ACM.2020.104104

参考文献

[1] Weimm, Z. (2016) Long Non-Coding RNA Sand Their Roles in Non-Small Cell Lung Cancer. Genomics Proteomics Bioinformatics, 14, 280-288. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. [Google Scholar] [CrossRef] [PubMed]
[3] 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1): 1-14.
[4] He, X.R., Han, S.Y. and Li, P.P. (2017) Recent Highlights of Chinese Medicine for Advanced Lung Cancer. Chinese Journal of Integrative Medicine, 23, 323-330. [Google Scholar] [CrossRef] [PubMed]
[5] Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2016) Gefitinib or Carboplatin-Paclitaxelin Pulmonary Adenocarcinoma. Oncotarget, 7, 41691-41702.
[6] Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine, 361, 947-957. [Google Scholar] [CrossRef] 
[7] Zhou, C., Wu, Y.L., Chen, G., et al. (2011) Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study. The Lancet Oncology, 12, 735-742. [Google Scholar] [CrossRef] 
[8] Wu, Y.L., Zhou, C., Liam, C.K., et al. (2015) First-Line Erlotinib versus Gemcitabine/Cisplatin in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Analyses from the Phase III, Randomized, Open-Label, ENSURE Study. Annals of Oncology, 26, 1883-1889. [Google Scholar] [CrossRef] [PubMed]
[9] Miller, V.A., Hirsh, V., Cadranel, J., et al. (2012) Afatinib versus Placebo for Patients with Advanced, Metastatic Non-Small Cell Lung Cancer after Failure of Erlotinib, Gefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial. The Lancet Oncology, 13, 528-538. [Google Scholar] [CrossRef] 
[10] Janne, P.A., Ou, S.H., Kim, D.W., et al. (2014) Dacomitinib as First-Line Treatment in Patients with Clinically or Molecularly Selected Advanced Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 15, 1433-1441. [Google Scholar] [CrossRef] 
[11] Mok, T.S., Wu, Y.L., Ahn, M.J., et al. (2017) Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine, 76, 629-640. [Google Scholar] [CrossRef] 
[12] J?nne, P.A., Yang, J.C., Kim, D.W., et al. (2015) AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 1689-1699. [Google Scholar] [CrossRef] 
[13] Yang, J., Ramalingam, S.S., J?nne, P.A., et al. (2016) LBA2-PR: Osimertinib (AZD9291) in Pre-Treated PTS with T790M Positive Advanced NSCLC: Updated Phase 1 (P1) and Pooled Phase 2 (P2) Results. Journal of Thoracic Oncology, 11, S152-S153. [Google Scholar] [CrossRef] 
[14] Soria, J.C., Ohe, Y., Vansteenkiste, J., et al. (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medi-cine, 378, 113-125. [Google Scholar] [CrossRef] 
[15] 徐婷, 孙大兴. 非小细胞肺癌的中医药治疗进展[J]. 浙江中医杂志, 2011, 46(8): 614-617.
[16] 刘嘉湘. 辨证治疗原发性肺癌 310 例疗效分析[J]. 上海中医药杂志, 1985(10): 3-5.
[17] 刘嘉湘. 益肺抗瘤饮治疗 271 例非小细胞肺癌临床观察[J]. 上海中医药杂志, 2001, 35(2): 4-6.
[18] 康小红, 王丽芳, 王中奇, 等. 肺炎宁方延缓 TKIs 靶向治疗晚期肺腺癌耐药的临床观察[J]. 新中医, 2012, 44(9): 52-54.
[19] 张梅, 张慧敏. 益气通络解毒方联合 EGFR-TKI 靶向治疗非小细胞肺癌的临床研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2014: 35.
[20] 房芳, 陈红, 赵辉, 等. 吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌的临床观察[J]. 中国现代医学杂志, 2011, 21(7): 883-886.
[21] 贾英杰, 黄敏娜, 孙一予, 等. 厄洛替尼联合消岩汤加减方治疗非小细胞肺癌的临床观察[J]. 中国医药指南, 2011, 9(35): 23-24.
[22] 尤建良. 晚期肺癌靶向治疗时中医药的切入[J]. 辽宁中医杂志, 2006, 33(10): 1228-1229.
[23] 周晓蓉, 徐士玲, 刘建红, 等. 复方锡类散液保留灌肠治疗化疗引起的严重腹泻[J]. 临床肿瘤学杂志, 2005, 10(5): 540-541.
[24] 张琇文, 邵怿, 张欣欣, 等. 参苓白术颗粒联合吉非替尼/厄罗替尼治疗脾气虚型晚期非小细胞肺癌临床研究[J]. 新中医, 2014, 46(1): 127-129.
[25] 王雄文, 陈日辉. 23 例吉非替尼相关皮疹中医辨证治疗分析[J]. 内蒙古中医药, 2008, 27(24): 9-10.
[26] 梁翠微, 杨兵, 杜均祥, 等. 吉非替尼相关皮疹的中医辨证论治[J]. 中国实用医药, 2011, 6(16): 22-23.
[27] 邱玉梅. 裴氏黄白散治疗易瑞沙所致皮肤不良反应的疗效观察[J]. 西部中医药, 2012, 25(11): 80-82.

为你推荐